FDA approves Sun Pharma ’s tildrakizumab for moderate-to-severe plaque psoriasis

Indian company Sun Pharmaceutical Industries has received the US Food and Drug Administration (FDA) approval of the Biologics License Application (BLA) for tildrakizumab to treat patients with moderate-to-severe plaque psoriasis.
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news